China Regenerative Medicine Intl : Professor Andrey Alekseev, Chairman of Russian National Burn Association - Visits Shaanxi Aierfu ActivTissue Engineering Co., Ltd., a Subsidiary of China Regenerative Medicine

[Group News] China Regenerative Medicine International Limited (Stock Code: 8158.HK) Professor Andrey Alekseev, Chairman of Russian National Burn Association Visits Shaanxi Aierfu ActivTissue Engineering Co., Ltd., a Subsidiary of China Regenerative Medicine

Hong Kong, 14 August 2017 - China Regenerative Medicine International Limited ("China Regenerative Medicine" or "the Company", stock code: 8158.HK, together with its subsidiaries, collectively "the Group") is pleased to announce that Professor Andrey Alekseev, Chairman of Russian National Burn Association, led a delegation to visit Shaanxi Aierfu ActivTissue Engineering Co., Ltd. for the technical cooperation with China Regenerative Medicine International Limited. Prof. Andrey Alekseev highly praised the Group's R&D, favorable clinical application outcomes and extensive application market of "ActivSkin", the only tissue-engineered skin with living cells in China, and he looked forward to introducing China's high-tech tissue-engineered products to Russia as early as possible with an aim to benefit more Russian patients.

Mr. Wang Zhengqun, General Manager (fourth left), Mr. Zhang Aibing, Vice President (fifth left), Prof. Andrey Alekseev and his wife (sixth left, seventh left), Prof. Panteleev (fifth right), Andrey (fourth right), Anton (third right)

The representatives of the delegation also included the wife of Prof. Andrey Alekseev, Prof. Panteleev, Head of Laboratory Russia Kurchatov Institute, Anton and Andrey, the representatives of TitanMed Company. Accompanied by Mr. Zhang Aibing, Vice President of the Group, and Mr. Wang Zhengqun, General Manager of Aierfu ActivTissue Engineering Co., Ltd., the delegation visited the industrialization base of "ActivSkin", the only tissue-engineered skin with living cells in China. The technical personnel explained to the delegation the production technology and process of "ActivSkin" in details. The delegation was impressed by the large scale, high tech, and modernized production lines of AiNear; Mr. Zhang Aibing, also introduced other products to the delegation, including Bio-engineered Cornea - "Acornea", Calcined Bovine Bone - "Gegreen", Acellular Anal Fistula Repair Stroma - "Asiunin" and Bioactive Cosmetics

- "Aimiya". The delegation showed a strong interest in the products series of the Group. After having a thorough understanding of the products, Xiao Houan, expert representative of "ActivSkin" clinical application, Officer of the Burn & Plastic Surgery Department at the Ninth Hospital of Xi'an Affiliated to Xi'an Jiaotong University Health Science Center, Chairman of the Committee of Xi'an Burn & Plastic Association, the knowledge sharing and exchange definitely enhanced the delegation's understanding on the clinical application of "ActivSkin" more specifically.

Visiting 'ActivSkin' production department

After the academic exchang activity, Mr. Zhang Aibing and Mr. Wang Zhengqun accompanied the delegation to visit the clinical application demonstration unit of "ActivSkin", namely Ninth Hospital of Xi'an Affiliated to Xi'an Jiaotong University Health Science Center and Xijing Hospital Affiliated to the Fourth Military Medical University. Prof. Andrey Alekseev exchanged professional and academic ideas with related staff at the two hospitals and introduced the development of Russian Burn Emergency Center and the treatment condition of burns in detail. In the meantime, Officer Xiao at the Ninth Hospital of Xi'an led the delegation into the department where doctors of Burn & Plastic Surgery Department presented the process of using "ActivSkin". While

at Xijing Hospital, Professor Hu Dahai, Head of Burn & Dermatologic Surgery Department and Chairman of the Committee of National Burn Society, had an in-depth technical discussion with Prof. Andrey Alekseev and others in the group, and also in detail introduced the burn research progress in China and the clinical application of "ActivSkin".

Mr. Zhang Aibing, Vice President, introduced series of product of the Group

Prof. Andrey Alekseev, Chairman of the Russian National Burn Association said, "We believe Aierfu's high-tech and up-to-date production technology and conditions, satisfactory clinical effect of the tissue-engineered skin 'ActivSkin', together with its broad market application prospect, will make contribution to human society. We look forward to introducing such technology to Russia as early as possible which would be beneficial to our patients. Through this visit, we can see strong teamwork spirit and professional working attitude among staff at China Regenerative Medicine International Limited. We look forward to further cooperation with the Group." Mr. Chen Chunguo, CEO of China Regenerative Medicine International Limited said, "Both parties will conduct deeper discussion in regard of further cooperation, with an aim to explore new areas of friendly cooperation between China and Russia as well as to promote the integrated development of modern medical technology in the international environment. This indicates that the Group's technologies with independent intellectual properties are gradually reaching out to the world and benefiting human beings."

- End -

About China Regenerative Medicine International Limited

China Regenerative Medicine International Limited，listed on the GEM Board of The

Stock Exchange, stock code :8158. China Regenerative Medicine is a high-end new- technology enterprise, principally engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The Group has accomplished the research and development and commercialization platform of tissue engineering and applied for more than 140 domestic and overseas patents on three major business segments, namely tissue engineering, cell therapy and cosmetics, including "ActivSkin", the only tissue-engineered skin developed in China, and "Acornea", the world's first bio-engineered cornea which completed its clinical trials. For more details, please visit www.crmi.hk.